L to R: Jeroen Bekaert, Ivan Dimov and Nate Fernhoff, Orca Bio (Orca)
Months after achieving unicorn status, Orca steers into the fast lane with an RMAT designation for cell therapy candidate
A few months after its last big catch — a $192 million Series D and rare unicorn status — Orca Bio has reeled in the FDA’s regenerative …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
